Holen Sie sich die Stockscreener-App
2.26
1.74%
-0.04
Vorhandelsmarkt:
2.28
0.02
+0.88%
Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten
Perspective Therapeutics (CATX) Gets a Hold from Bank of America Securities - The Globe and Mail
Perspective Therapeutics, Inc. (AAJ0.F) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Perspective Therapeutics, Inc. (AAJ0.F) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia
Perspective Therapeutics, Inc. (AAJ0.F) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Perspective Therapeutics (CATX) Receives a Buy from Wedbush - The Globe and Mail
Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Announces Target Price $11 - Moomoo
Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength? - Zacks Investment Research
With treatment options limited, a tumor therapy gets FDA Fast Track at Perspective Therapeutics (CATX). - Stock Titan
Perspective Therapeutics Granted Fast Track Designation for - GlobeNewswire
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors - Yahoo Finance
Perspective Therapeutics, Inc. (AAJ0.F) stock price, news, quote and history - Yahoo Finance UK
Perspective Therapeutics Announces NANETS 2026 Presentation of [212Pb]VMT-α-NET Clinical Data in Advanced Neuroendocrine Tumors - Quiver Quantitative
Cancer-treatment data will get an oral presentation at a November medical symposium. - Stock Titan
Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium - GlobeNewswire
UBS Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Perspective Therapeutics, Inc. (CATX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Perspective Therapeutics’ [212Pb]VMT01 Melanoma Data Accepted for Presentation at 2026 SITC Annual Meeting - Quiver Quantitative
A study of a targeted melanoma treatment will be presented at a cancer meeting in November. - Stock Titan
Perspective Therapeutics (CATX) Short Interest & Short Float | Updated Oct 2026 - marketbeat.com
Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026 - GlobeNewswire
Form 8K Perspective Therapeutics Inc For: 1 October By Investing.com - Investing.com Nigeria
Three cancer programs are in trials. Perspective Therapeutics (CATX) reports early melanoma results. - Stock Titan
Form 13D/A Perspective Therapeutics For: 26 September By Investing.com - Investing.com Nigeria
After selling nearly 1.4 million shares in one day, a Perspective Therapeutics (CATX) holder still has a stake. - Stock Titan
Perspective Therapeutics (NYSEAM:CATX)Stock Analysis - Simply Wall Street
Perspective Therapeutics, Inc.(NYSEAM:CATX) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
This $3 Biotech Could Be Worth $11.45, Analyst Says - Benzinga
William Blair Initiates Perspective Therapeutics With Outperform Rating - Yahoo Finance
William Blair initiates Perspective Therapeutics stock with outperform rating - Investing.com
Perspective Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate PSV359 in Combination with Keytruda in Advanced FAP-α-Positive Solid Tumors - Quiver Quantitative
Merck joins Perspective Therapeutics (NYSE: CATX) to test Keytruda combo in Phase 1/2a cancer trial - Stock Titan
Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell - Yahoo Finance
Perspective Therapeutics partners with Merck on cancer trial - Investing.com
Merck provides Keytruda at no cost for a cancer trial - Stock Titan
Perspective Therapeutics to present NET therapy trial data - grafa.com
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026 - Yahoo! Finance Canada
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026 - Yahoo Finance
Perspective Therapeutics Announces Acceptance of Updated [212Pb]VMT-α-NET Data for Presentation at 2026 ENA Symposium | CATX Stock News - Quiver Quantitative
Cancer-treatment data heads to Barcelona on Nov. 20 - Stock Titan
Perspective Therapeutics (CATX) Insider Sale: 10% Owner Lantheus Alpha Therapy, LLC Sells 247,932 Shares - GuruFocus
Perspective Therapeutics updates corporate presentation highlighting 212Pb pipeline, $45B addressable market - TradingView
Perspective Therapeutics (CATX) highlights 3 cancer drug programs - Stock Titan
Perspective Therapeutics (CATX) holder sells stock near $3.10 - Stock Titan
Lantheus Alpha Therapy Sells 113,914 Perspective Therapeutics (AMEX: CATX) Shares at Up to $3.14 Per Share - Kalkine Media
Lantheus Group Reduces Stake in Perspective Therapeutics (AMEX: CATX) to 10% Amid Activist 13D Filing - Kalkine Media
Lantheus Holdings (NASDAQ: LNTH) 10% Stakeholder Alpha Therapy Sells 42,129 Shares at $3.11 Each - Kalkine Media
Perspective Therapeutics (CATX) Insider Sell: 10% Owner Lantheus Alpha Therapy, LLC Disposes of 42,129 Shares - GuruFocus
Perspective Therapeutics (CATX) backer trims stake but keeps 11.5M shares - Stock Titan
10% owner of Perspective Therapeutics (NYSE: CATX) sells 113,914 shares over two days - Stock Titan
Perspective Therapeutics (CATX) backer Lantheus now owns 10% after share sales - Stock Titan
6.50%
3.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):